CD229 Antibodies

Santa Cruz Biotechnology provides a broad selection of CD229 monoclonal antibodies for advanced research in immunology and cell biology. CD229 monoclonal antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). CD229, also known as SLAM family member 1 (SLAMF1), plays a critical role in immune cell signaling and activation, particularly in T and B lymphocytes. CD229 is involved in regulating immune responses and maintaining the balance between activation and inhibition of immune cells, making it essential for effective immune function. Understanding CD229 function is crucial for investigating various immune-related diseases and developing targeted therapies. CD229 research has significant implications for autoimmune disorders, cancer immunotherapy, and infectious disease treatments. Ongoing studies of CD229 continue to reveal new insights into immune system regulation and potential therapeutic approaches. Santa Cruz Biotechnology monoclonal antibodies for CD229 support researchers worldwide in advancing scientific understanding of immune system function and disease mechanisms.